RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Xeris Pharmaceuticals Stock

Xeris Pharmaceuticals Revenue 2024

Xeris Pharmaceuticals Revenue

202.4 M USD

Ticker

XERS

ISIN

US98422L1070

WKN

A2JPE9

In 2024, Xeris Pharmaceuticals's sales reached 202.4 M USD, a 23.48% difference from the 163.91 M USD sales recorded in the previous year.

The Xeris Pharmaceuticals Revenue history

YEARREVENUE (undefined USD)GROSS MARGIN (%)
2029e398.4933,95
2028e364.0837,15
2027e314.2143,05
2026e285.547,38
2025e240.2356,31
2024e202.466,83
2023163.9182,52
2022110.279,49
202149.673,19
202020.454,41
20192.740,74
20182.596,00
20171.6100,00
20161.1100,00

Xeris Pharmaceuticals Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Xeris Pharmaceuticals, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Xeris Pharmaceuticals from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Xeris Pharmaceuticals’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Xeris Pharmaceuticals. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Xeris Pharmaceuticals’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Xeris Pharmaceuticals’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Xeris Pharmaceuticals’s growth potential.

Xeris Pharmaceuticals Revenue, EBIT and net profit per share

DateXeris Pharmaceuticals RevenueXeris Pharmaceuticals EBITXeris Pharmaceuticals Net Income
2029e398.49 M undefined155.16 M undefined148.94 M undefined
2028e364.08 M undefined101.83 M undefined80.55 M undefined
2027e314.21 M undefined70.66 M undefined48.25 M undefined
2026e285.5 M undefined31.92 M undefined9.5 M undefined
2025e240.23 M undefined-9.8 M undefined-33.74 M undefined
2024e202.4 M undefined-39.33 M undefined-62.62 M undefined
2023163.91 M undefined-44.01 M undefined-62.26 M undefined
2022110.2 M undefined-71.8 M undefined-94.7 M undefined
202149.6 M undefined-106.5 M undefined-122.7 M undefined
202020.4 M undefined-83.6 M undefined-91.1 M undefined
20192.7 M undefined-122.4 M undefined-125.6 M undefined
20182.5 M undefined-59.3 M undefined-60.1 M undefined
20171.6 M undefined-26.6 M undefined-26.6 M undefined
20161.1 M undefined-13.2 M undefined-13.2 M undefined

Xeris Pharmaceuticals stock margins

The Xeris Pharmaceuticals margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Xeris Pharmaceuticals. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Xeris Pharmaceuticals.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Xeris Pharmaceuticals's sales revenue. A higher gross margin percentage indicates that the Xeris Pharmaceuticals retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Xeris Pharmaceuticals's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Xeris Pharmaceuticals's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Xeris Pharmaceuticals's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Xeris Pharmaceuticals. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Xeris Pharmaceuticals's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Xeris Pharmaceuticals Margin History

Xeris Pharmaceuticals Gross marginXeris Pharmaceuticals Profit marginXeris Pharmaceuticals EBIT marginXeris Pharmaceuticals Profit margin
2029e82.52 %38.94 %37.38 %
2028e82.52 %27.97 %22.12 %
2027e82.52 %22.49 %15.36 %
2026e82.52 %11.18 %3.33 %
2025e82.52 %-4.08 %-14.04 %
2024e82.52 %-19.43 %-30.94 %
202382.52 %-26.85 %-37.98 %
202279.49 %-65.15 %-85.93 %
202173.19 %-214.72 %-247.38 %
202054.41 %-409.8 %-446.57 %
201940.74 %-4,533.33 %-4,651.85 %
201896 %-2,372 %-2,404 %
2017100 %-1,662.5 %-1,662.5 %
2016100 %-1,200 %-1,200 %

Xeris Pharmaceuticals Aktienanalyse

What does Xeris Pharmaceuticals do?

Xeris Pharmaceuticals Inc is a US pharmaceutical company that was founded in 2005. The company is headquartered in Chicago and is listed on the Nasdaq stock exchange. The business model of Xeris Pharmaceuticals is focused on providing patients and medical professionals with a wide range of products and services that improve patients' lives while promoting the development of effective and safe drugs. Xeris Pharmaceuticals focuses on the development of drugs made from peptides and proteins. The aim is to provide innovative drugs to patients with rare diseases or unmet therapeutic needs. Over the years, Xeris Pharmaceuticals has diversified into various sectors. One of the most important sectors is the diabetes industry. In this area, the company offers the Gvoke product family, a lightweight auto-injection method designed for adults, adolescents, and children with type 1 diabetes, as well as adults with type 2 diabetes. The Gvoke product is intended for patients with severe hypoglycemia and provides a quick and easy way to treat life-threatening hypoglycemic episodes. Another important sector for Xeris Pharmaceuticals is the neurology industry. In this area, the company has developed an injection device called XeriSol, specifically designed for the treatment of epilepsy or neurological seizures. The active ingredient used is diazepam, which has a rapid and reliable effect on seizures. Xeris Pharmaceuticals is also involved in cancer treatment. The company has developed a pituitary hormone analog called Pasireotide, which is used to treat Cushing's disease, a rare condition caused by hormone overproduction. The drug fits well into Xeris Pharmaceuticals' business model as it is peptide-based and offers better efficacy and safety than other drugs in this area. Overall, Xeris Pharmaceuticals has a strong pipeline of drugs that offer the company great potential for future growth. The development of innovative drugs and drug combinations is an important strategy for Xeris Pharmaceuticals to help patients with rare diseases or unmet therapeutic needs. In this regard, Xeris Pharmaceuticals has also formed partnerships with other leading pharmaceutical companies such as Sanofi, Eli Lilly, and Roche. These partnerships allow the company to accelerate its drug development and offer its products in the international market. In conclusion, the success story of Xeris Pharmaceuticals shows that the company is an important player in the pharmaceutical industry and plays a crucial role in the development of innovative, safe, and effective drugs for patients with rare diseases and unmet therapeutic needs. With its wide range of products, partnerships, and strong pipeline of innovative drugs, Xeris Pharmaceuticals is a company that has great potential for successful growth in the future. Xeris Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Revenue Details

Understanding Xeris Pharmaceuticals's Sales Figures

The sales figures of Xeris Pharmaceuticals originate from the total revenue accrued from goods sold or services provided during a specific time period. These numbers are a direct reflection of the company’s ability to translate its products or services into revenue, indicating the demand and market presence.

Year-to-Year Comparison

Analyzing Xeris Pharmaceuticals’s yearly sales data offers insights into the company’s growth and stability. An increase in sales suggests a growing demand for its offerings, efficient marketing, or expansion into new markets. Conversely, a decline might indicate market saturation, increased competition, or less effective strategies.

Impact on Investments

Investors often scrutinize Xeris Pharmaceuticals's sales data to evaluate its financial health and growth prospects. Consistent sales growth can be a promising indicator of the company’s profitability and potential return on investment, influencing stock prices and investor confidence.

Interpreting Sales Fluctuations

Increases in Xeris Pharmaceuticals’s sales indicate market growth, innovation, or effective marketing, often leading to a surge in stock prices. A decline, however, can signal challenges requiring strategic adjustments to enhance market share and profitability.

Frequently Asked Questions about Xeris Pharmaceuticals stock

How much revenue did Xeris Pharmaceuticals generate this year?

Xeris Pharmaceuticals has achieved a revenue of 202.4 M USD this year.

How much was the turnover of the company Xeris Pharmaceuticals compared to the previous year?

The revenue of Xeris Pharmaceuticals has increased by 23.48% increased compared to the previous year.

What does revenue mean for investors?

The revenue of a company is an important indicator of its financial performance and attractiveness for investors.

Which factors influence the revenue of Xeris Pharmaceuticals?

The revenue of Xeris Pharmaceuticals is influenced by various factors, including the demand for its products and services, market conditions, and prices.

How is the revenue of Xeris Pharmaceuticals measured?

Revenue is typically measured in units referring to the sale of goods and services provided by the company.

How does an increase in sales affect investments?

An increase in revenue can prompt investors to invest more money in the company as it serves as a positive signal for its financial performance and growth prospects.

What are the possible risks associated with a declining revenue?

A decline in revenue can prompt investors to invest less money in the company, as it is a negative signal for its financial performance and growth prospects.

Why is the sales revenue of Xeris Pharmaceuticals so important for investors?

The revenue of Xeris Pharmaceuticals is an important indicator of financial performance and attractiveness for investors.

What strategic measures can a company take to increase revenue?

A company can take various strategic measures to increase revenue, including developing new products and services, introducing new pricing models, and expanding into new markets.

How much dividend does Xeris Pharmaceuticals pay?

Over the past 12 months, Xeris Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Xeris Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Xeris Pharmaceuticals?

The current dividend yield of Xeris Pharmaceuticals is .

When does Xeris Pharmaceuticals pay dividends?

Xeris Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Xeris Pharmaceuticals?

Xeris Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Xeris Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Xeris Pharmaceuticals located?

Xeris Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Xeris Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Xeris Pharmaceuticals from 12/4/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 12/4/2024.

When did Xeris Pharmaceuticals pay the last dividend?

The last dividend was paid out on 12/4/2024.

What was the dividend of Xeris Pharmaceuticals in the year 2023?

In the year 2023, Xeris Pharmaceuticals distributed 0 USD as dividends.

In which currency does Xeris Pharmaceuticals pay out the dividend?

The dividends of Xeris Pharmaceuticals are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Xeris Pharmaceuticals stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Xeris Pharmaceuticals

Our stock analysis for Xeris Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Xeris Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.